OP Asset Management Ltd Buys Shares of 55,082 Xencor, Inc. $XNCR

OP Asset Management Ltd bought a new position in shares of Xencor, Inc. (NASDAQ:XNCR) in the 1st quarter, Holdings Channel.com reports. The institutional investor bought 55,082 shares of the biopharmaceutical company’s stock, valued at approximately $664,000.

A number of other hedge funds have also modified their holdings of XNCR. ProShare Advisors LLC grew its holdings in Xencor by 6.5% during the fourth quarter. ProShare Advisors LLC now owns 16,853 shares of the biopharmaceutical company’s stock valued at $258,000 after purchasing an additional 1,026 shares during the period. Cerity Partners LLC grew its holdings in shares of Xencor by 3.8% in the 4th quarter. Cerity Partners LLC now owns 31,302 shares of the biopharmaceutical company’s stock valued at $479,000 after buying an additional 1,143 shares during the period. State of Tennessee Department of Treasury increased its position in shares of Xencor by 6.2% in the 2nd quarter. State of Tennessee Department of Treasury now owns 30,721 shares of the biopharmaceutical company’s stock valued at $241,000 after buying an additional 1,784 shares in the last quarter. Diversified Trust Co. raised its stake in Xencor by 13.8% during the 4th quarter. Diversified Trust Co. now owns 18,442 shares of the biopharmaceutical company’s stock worth $282,000 after buying an additional 2,242 shares during the period. Finally, CANADA LIFE ASSURANCE Co increased its holdings in shares of Xencor by 3.3% in the second quarter. CANADA LIFE ASSURANCE Co now owns 70,015 shares of the biopharmaceutical company’s stock worth $550,000 after acquiring an additional 2,256 shares in the last quarter.

Analysts Set New Price Targets

XNCR has been the topic of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xencor in a research report on Wednesday, June 24th. Wall Street Zen downgraded shares of Xencor from a “hold” rating to a “strong sell” rating in a report on Saturday, May 9th. Zacks Research lowered Xencor from a “hold” rating to a “strong sell” rating in a research report on Wednesday, May 6th. Finally, JPMorgan Chase & Co. upped their price objective on Xencor from $13.00 to $14.00 and gave the stock a “neutral” rating in a research note on Monday, May 11th. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $24.50.

Xencor Stock Up 3.2%

Shares of NASDAQ XNCR opened at $16.10 on Wednesday. The business’s 50 day moving average price is $12.45 and its two-hundred day moving average price is $12.81. The company has a market cap of $1.19 billion, a PE ratio of -7.03 and a beta of 0.92. Xencor, Inc. has a twelve month low of $6.92 and a twelve month high of $18.69.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.96). Xencor had a negative net margin of 177.10% and a negative return on equity of 28.77%. The business had revenue of $4.52 million during the quarter, compared to analyst estimates of $27.86 million. During the same period in the previous year, the business earned ($0.66) earnings per share. The business’s quarterly revenue was down 86.2% on a year-over-year basis. As a group, research analysts anticipate that Xencor, Inc. will post -3.84 EPS for the current fiscal year.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.